Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.67 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | YAP1 | P46937 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5450185 | 0.94 | FAAH (0.77) | FAAHENPP2P2RX3MAOBYAP1 | |
| SCHEMBL5451889 | 0.88 | FAAH (0.57) | FAAHENPP2MAOBHDAC1HDAC8 | |
| SCHEMBL5447729 | 0.87 | FAAH (0.88) | FAAHENPP2P2RX3MAOB | |
| SCHEMBL4308368 | 0.83 | HRH3 (0.53) | FAAHENPP2HDAC1HDAC8HRH3 | |
| SCHEMBL5451896 | 0.82 | FAAH (0.65) | FAAHMAOBTEAD1 | |
| SCHEMBL5447912 | 0.82 | FAAH (0.62) | FAAHHDAC1HDAC8 | |
| SCHEMBL13279636 | 0.81 | GPR119 (0.52) | FAAHTGFBR1 | |
| SCHEMBL5451937 | 0.81 | FAAH (1.00) | FAAHENPP2P2RX3MAOB | |
| SCHEMBL2463086 | 0.80 | FAAH (0.52) | FAAHYAP1HDAC1CYP11B1CYP11B2 | |
| SCHEMBL5455256 | 0.80 | FAAH (0.68) | FAAHENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021405-A1 | ARYL- AND HETEROARYLPIPERIDINECARBOXYLATE-DERIVATIVES METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021405-A1 | ARYL- AND HETEROARYLPIPERIDINECARBOXYLATE-DERIVATIVES METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, HRH2 | FAAH 1/4885ENPP2 14/4885P2RX3 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.